Mineral and bone disorder is the part of CKD that reaches beyond the kidney into the skeleton and the arteries. It starts silently and early, with a rise in a hormone most clinicians never measure, and it ends — if uncontrolled — in calcified vessels and fractured bones, contributing heavily to the cardiovascular death that dominates CKD. Understanding the cascade is what makes the treatment make sense, and the treatment is a balancing act: lower phosphate and control parathyroid hormone without loading calcium or over-suppressing the bone.
The cascade: FGF23, calcitriol, and PTH
The disturbance unfolds in a sequence. As GFR falls, the kidney's capacity to excrete phosphate is threatened, and the body's first defence is FGF23, secreted by osteocytes, which is phosphaturic — it drives phosphate out in the urine to keep the serum level normal. FGF23 rises before phosphate does, making it the earliest change, and it comes at a cost: it suppresses the kidney's 1-alpha-hydroxylase, reducing the activation of vitamin D. So calcitriol, the active form, falls — both because the failing kidney activates less of it and because FGF23 suppresses the enzyme. Low calcitriol reduces intestinal calcium absorption, lowering serum calcium, and removes calcitriol's direct brake on the parathyroid glands. The result is that three signals converge on the parathyroids — the phosphate retention that eventually appears, the falling calcium, and the falling calcitriol — and all of them stimulate PTH. This is secondary hyperparathyroidism, and the loss of Klotho, the FGF23 co-receptor made in the kidney and depleted early, adds a layer of FGF23 resistance to the picture.
From secondary to tertiary, and the bone
Sustained stimulation does to the parathyroid glands what it does to any chronically driven endocrine tissue: it makes them grow. The glands hyperplase, and over time can become autonomous, secreting PTH independent of the signals that first drove them — tertiary hyperparathyroidism, now with hypercalcaemia because the gland no longer responds to the feedback. Meanwhile the bone suffers, in a spectrum called renal osteodystrophy classified by three features — turnover, mineralisation, and volume. High PTH produces a high-turnover bone disease, osteitis fibrosa, with excessive resorption. At the other end is low-turnover adynamic bone, where PTH has been suppressed too far — often by over-treatment — and the bone becomes inert. Bone biopsy is the gold standard for classifying these, but it is rarely performed, and the laboratory values cannot reliably distinguish the types, which is part of why management aims at ranges rather than precision.
Vascular calcification: the deadly endpoint
The component that kills is the vascular one. A high phosphate, a high calcium-phosphate product, an excess calcium load, and the loss of circulating calcification inhibitors such as fetuin-A and matrix Gla protein together push vascular smooth-muscle cells to transdifferentiate into osteoblast-like cells that lay down calcium in the arterial wall. The result is medial calcification, which stiffens the arteries, raises pulse pressure and cardiac afterload, and contributes substantially to the cardiovascular mortality that is the leading cause of death in CKD. This is the reason CKD-MBD is not a niche metabolic curiosity but a driver of the outcome that matters most — and the reason that avoiding calcium load and controlling phosphate are framed as cardiovascular, not merely skeletal, interventions.
Monitoring: trends, not single values
The mineral panel — calcium, phosphate, PTH, alkaline phosphatase, and vitamin D — is monitored at a frequency that rises with CKD stage, and the cardinal rule is to treat trends and the whole picture rather than reacting to single values. PTH is the hardest to interpret: the optimal level in CKD is genuinely uncertain, and in dialysis a range of roughly two to nine times the upper normal is targeted precisely because both over- and under-suppression cause harm. A rising PTH trend is more informative than an isolated number and prompts action; alkaline phosphatase helps gauge bone turnover. Imaging for vascular calcification — a lateral abdominal radiograph or echocardiography — identifies the high-cardiovascular-risk patient. The diagnostic discipline is patience with the numbers and attention to direction.
Controlling phosphate
Phosphate is the lever with the most evidence behind it, and control is dietary and pharmacological. Dietary phosphate restriction targets especially the inorganic phosphate additives in processed food, which are far more bioavailable than the organic phosphate of natural foods — and plant phosphate, bound as phytate, is less absorbed still, one reason plant-dominant diets help here. Phosphate binders, taken with meals to bind dietary phosphate in the gut, are the mainstay when diet is insufficient. The binder choice matters: calcium-based binders are cheap and effective but add to the calcium load that drives vascular calcification, so guidelines suggest restricting them; non-calcium binders such as sevelamer (which also lowers LDL cholesterol) and lanthanum avoid the calcium load; iron-based binders bind phosphate and provide iron; and aluminium binders, historically toxic, are avoided. The priority is to lower elevated phosphate toward normal while limiting calcium loading.
PTH: suppress, but not too far
Controlling PTH is where the balancing act is sharpest, because the two drug classes pull calcium in opposite directions. Active vitamin D analogues — calcitriol, alfacalcidol, and the more selective paricalcitol — suppress PTH effectively but raise serum calcium and phosphate, risking hypercalcaemia and adding to the calcification load. Calcimimetics — cinacalcet by mouth, etelcalcetide intravenously in dialysis — activate the calcium-sensing receptor on the parathyroid gland, suppressing PTH while lowering calcium and phosphate, an advantage in the patient who is already calcium-loaded. The overarching caution is not to over-suppress: driving PTH too low, whether with vitamin D, calcium, or a calcimimetic, produces adynamic bone, which cannot buffer calcium and so worsens hypercalcaemia, vascular calcification, and fracture risk. Some elevation of PTH is necessary to maintain bone turnover, so the target is control, not normalisation. When hyperparathyroidism becomes severe and refractory to medical therapy — particularly tertiary disease — parathyroidectomy is the definitive option.
Where the evidence is firm, and where it is soft
The firm parts are the associations and the principles: hyperphosphataemia and vascular calcification are robustly linked to cardiovascular mortality, calcium loading promotes calcification, and over-suppression of PTH causes adynamic bone. The soft parts are the targets and the hard outcomes. The ideal PTH, calcium, and phosphate levels are defined by consensus and association rather than by trials showing that hitting them improves survival, and the major trial of a calcimimetic did not significantly reduce its primary cardiovascular endpoint. So practice rests on lowering phosphate toward normal, avoiding hypercalcaemia and calcium load, controlling rather than normalising PTH, and individualising — confident in the direction of travel even where the precise target and the mortality benefit remain incompletely proven.
